Overview

MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)

Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if pembrolizumab (also called MK-3475 and Keytruda) can help to control metastatic IBC. The safety of this drug will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab